Advarra purchases IntegReview IRB

By Jenni Spinner

- Last updated on GMT

(RG-vc/iStock via Getty Images Plus)
(RG-vc/iStock via Getty Images Plus)

Related tags advarra Institutional review board acquisition Clinical trials Research

The institutional review board services provider has acquired the AAHRPP-accredited central IRB, which specializes in early-phase research.

Advarra provides institutional review board (IRB), institutional biosafety committee (IBC), quality and compliance consulting services, as well as research technology solutions. The addition of IntegReview IRB, with a focus on early-phase clinical research, reportedly will enable Advarra to further its expansion of review solutions capability offerings in North America.

Gadi Saarony, Advarra’s CEO, said the two firms share a mission and focus, including ensuring patient participants are protected.

Our aim is to benefit clinical trials and drug development through expanded subject matter expertise, technology-enabled efficiencies, and continuing commitment to ethics, quality, and service​,” he said.

The current Austin, Texas, headquarters for IntegReview IRB will become the first Advarra office in the southern US. According to the companies, the acquisition also increases and explands Advarra’s depth of expertise in many areas, including early-phase research.

We are excited to be a part of the Advarra family,​” said Lynn Meyer, founder and managing partner of IntegReview IRB. “We were attracted to Advarra’s extensive regulatory depth and their model of integrated IRB operations and focus on building client relationships and deep collaboration with the site community​.”

According to Advarra, the expanded capabilities afforded by the acquisition stands to help them provide clients in the research community and biopharma industry with integrated solutions to advance healthcare. Additionally, the purchase reportedly enables Advarra to extend its regulatory compliance expertise and further increase its reach, serving more than 3,200 research institutions, hospital systems, and academic medical centers.

Scott Uebele, president and CRSO of Advarra Research Services, said, “Integrating IntegReview into Advarra will take approximately six months and immediately augments our early phase board expertise. IntegReview’s demonstrated knowledge and reputation in clinical pharmacology offers Advarra clients exceptional service for IRB review during early development and ensures the highest quality ethical oversight and participant safety​.”

In May 2020, Advarra acquired IRBco, another accredited central IRB​.

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more